vs
AerSale Corp（ASLE）与VERACYTE, INC.（VCYT）财务数据对比。点击上方公司名可切换其他公司
VERACYTE, INC.的季度营收约是AerSale Corp的1.5倍（$140.6M vs $90.9M），VERACYTE, INC.净利率更高（29.3% vs 5.9%，领先23.3%），VERACYTE, INC.同比增速更快（18.5% vs -4.0%），VERACYTE, INC.自由现金流更多（$48.8M vs $9.8M），过去两年VERACYTE, INC.的营收复合增速更高（20.5% vs 0.2%）
AerSale Corp总部位于美国佛罗里达州多拉市，是一家面向航空领域的全球供应商，主要为客运及货运航空公司、政府机构、跨国整机制造商与独立维修机构提供商用喷气飞机二手整机、发动机、航空耗材，并提供航空工程服务，同时该公司也是飞机机队回收协会的成员企业。
Veracyte是一家领先的分子诊断企业，专注开发专有的基因组检测方案，可实现癌症及其他复杂疾病的早期精准检测，产品服务于医疗机构以优化临床决策，核心市场位于美国，正稳步拓展全球业务布局。
ASLE vs VCYT — 直观对比
营收规模更大
VCYT
是对方的1.5倍
$90.9M
营收增速更快
VCYT
高出22.6%
-4.0%
净利率更高
VCYT
高出23.3%
5.9%
自由现金流更多
VCYT
多$39.0M
$9.8M
两年增速更快
VCYT
近两年复合增速
0.2%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $90.9M | $140.6M |
| 净利润 | $5.4M | $41.1M |
| 毛利率 | 34.1% | 72.5% |
| 营业利润率 | 7.8% | 26.4% |
| 净利率 | 5.9% | 29.3% |
| 营收同比 | -4.0% | 18.5% |
| 净利润同比 | 99.7% | 704.8% |
| 每股收益（稀释后） | $0.10 | $0.50 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ASLEVCYT
| Q4 25 | $90.9M | $140.6M | ||
| Q3 25 | $71.2M | $131.9M | ||
| Q2 25 | $107.4M | $130.2M | ||
| Q1 25 | $65.8M | $114.5M | ||
| Q4 24 | $94.7M | $118.6M | ||
| Q3 24 | $82.7M | $115.9M | ||
| Q2 24 | $77.1M | $114.4M | ||
| Q1 24 | $90.5M | $96.8M |
净利润ASLEVCYT
| Q4 25 | $5.4M | $41.1M | ||
| Q3 25 | $-120.0K | $19.1M | ||
| Q2 25 | $8.6M | $-980.0K | ||
| Q1 25 | $-5.3M | $7.0M | ||
| Q4 24 | $2.7M | $5.1M | ||
| Q3 24 | $509.0K | $15.2M | ||
| Q2 24 | $-3.6M | $5.7M | ||
| Q1 24 | $6.3M | $-1.9M |
毛利率ASLEVCYT
| Q4 25 | 34.1% | 72.5% | ||
| Q3 25 | 30.2% | 69.2% | ||
| Q2 25 | 32.9% | 69.0% | ||
| Q1 25 | 27.3% | 69.5% | ||
| Q4 24 | 31.4% | 66.4% | ||
| Q3 24 | 28.6% | 68.2% | ||
| Q2 24 | 28.2% | 68.1% | ||
| Q1 24 | 31.8% | 64.5% |
营业利润率ASLEVCYT
| Q4 25 | 7.8% | 26.4% | ||
| Q3 25 | 4.0% | 17.4% | ||
| Q2 25 | 11.7% | -4.0% | ||
| Q1 25 | -10.1% | 2.5% | ||
| Q4 24 | 5.2% | 3.5% | ||
| Q3 24 | 2.4% | 10.4% | ||
| Q2 24 | -2.4% | 4.0% | ||
| Q1 24 | 5.2% | -4.8% |
净利率ASLEVCYT
| Q4 25 | 5.9% | 29.3% | ||
| Q3 25 | -0.2% | 14.5% | ||
| Q2 25 | 8.0% | -0.8% | ||
| Q1 25 | -8.0% | 6.2% | ||
| Q4 24 | 2.9% | 4.3% | ||
| Q3 24 | 0.6% | 13.1% | ||
| Q2 24 | -4.7% | 5.0% | ||
| Q1 24 | 6.9% | -1.9% |
每股收益（稀释后）ASLEVCYT
| Q4 25 | $0.10 | $0.50 | ||
| Q3 25 | $0.00 | $0.24 | ||
| Q2 25 | $0.18 | $-0.01 | ||
| Q1 25 | $-0.10 | $0.09 | ||
| Q4 24 | $0.05 | $0.07 | ||
| Q3 24 | $0.01 | $0.19 | ||
| Q2 24 | $-0.07 | $0.07 | ||
| Q1 24 | $0.12 | $-0.02 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $4.4M | $362.6M |
| 总债务越低越好 | $1.3M | — |
| 股东权益账面价值 | $424.4M | $1.3B |
| 总资产 | $640.5M | $1.4B |
| 负债/权益比越低杠杆越低 | 0.00× | — |
8季度趋势，按日历期对齐
现金及短期投资ASLEVCYT
| Q4 25 | $4.4M | $362.6M | ||
| Q3 25 | $5.3M | $315.6M | ||
| Q2 25 | $5.7M | $219.5M | ||
| Q1 25 | $4.7M | $186.1M | ||
| Q4 24 | $4.7M | $239.1M | ||
| Q3 24 | $9.8M | $274.1M | ||
| Q2 24 | $4.3M | $235.9M | ||
| Q1 24 | $2.6M | $209.2M |
总债务ASLEVCYT
| Q4 25 | $1.3M | — | ||
| Q3 25 | $1.5M | — | ||
| Q2 25 | $907.0K | — | ||
| Q1 25 | $1.1M | — | ||
| Q4 24 | $1.2M | — | ||
| Q3 24 | $376.0K | — | ||
| Q2 24 | $522.0K | — | ||
| Q1 24 | $3.5M | — |
股东权益ASLEVCYT
| Q4 25 | $424.4M | $1.3B | ||
| Q3 25 | $417.1M | $1.3B | ||
| Q2 25 | $415.9M | $1.2B | ||
| Q1 25 | $406.5M | $1.2B | ||
| Q4 24 | $455.6M | $1.2B | ||
| Q3 24 | $451.5M | $1.2B | ||
| Q2 24 | $449.8M | $1.1B | ||
| Q1 24 | $452.0M | $1.1B |
总资产ASLEVCYT
| Q4 25 | $640.5M | $1.4B | ||
| Q3 25 | $646.3M | $1.4B | ||
| Q2 25 | $646.7M | $1.3B | ||
| Q1 25 | $646.1M | $1.3B | ||
| Q4 24 | $604.7M | $1.3B | ||
| Q3 24 | $601.5M | $1.3B | ||
| Q2 24 | $598.7M | $1.2B | ||
| Q1 24 | $571.7M | $1.2B |
负债/权益比ASLEVCYT
| Q4 25 | 0.00× | — | ||
| Q3 25 | 0.00× | — | ||
| Q2 25 | 0.00× | — | ||
| Q1 25 | 0.00× | — | ||
| Q4 24 | 0.00× | — | ||
| Q3 24 | 0.00× | — | ||
| Q2 24 | 0.00× | — | ||
| Q1 24 | 0.01× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $11.4M | $52.6M |
| 自由现金流经营现金流 - 资本支出 | $9.8M | $48.8M |
| 自由现金流率自由现金流/营收 | 10.8% | 34.7% |
| 资本支出强度资本支出/营收 | 1.7% | 2.7% |
| 现金转化率经营现金流/净利润 | 2.11× | 1.28× |
| 过去12个月自由现金流最近4个季度 | $-29.1M | $126.6M |
8季度趋势，按日历期对齐
经营现金流ASLEVCYT
| Q4 25 | $11.4M | $52.6M | ||
| Q3 25 | $-8.9M | $44.8M | ||
| Q2 25 | $19.8M | $33.6M | ||
| Q1 25 | $-45.2M | $5.4M | ||
| Q4 24 | $37.5M | $24.5M | ||
| Q3 24 | $10.4M | $30.0M | ||
| Q2 24 | $-15.3M | $29.6M | ||
| Q1 24 | $-21.5M | $-9.0M |
自由现金流ASLEVCYT
| Q4 25 | $9.8M | $48.8M | ||
| Q3 25 | $-9.8M | $42.0M | ||
| Q2 25 | $18.6M | $32.3M | ||
| Q1 25 | $-47.6M | $3.5M | ||
| Q4 24 | $32.3M | $20.4M | ||
| Q3 24 | $8.9M | $27.7M | ||
| Q2 24 | $-18.9M | $26.8M | ||
| Q1 24 | $-25.0M | $-11.1M |
自由现金流率ASLEVCYT
| Q4 25 | 10.8% | 34.7% | ||
| Q3 25 | -13.8% | 31.8% | ||
| Q2 25 | 17.3% | 24.8% | ||
| Q1 25 | -72.4% | 3.1% | ||
| Q4 24 | 34.0% | 17.2% | ||
| Q3 24 | 10.7% | 23.9% | ||
| Q2 24 | -24.6% | 23.4% | ||
| Q1 24 | -27.7% | -11.5% |
资本支出强度ASLEVCYT
| Q4 25 | 1.7% | 2.7% | ||
| Q3 25 | 1.3% | 2.1% | ||
| Q2 25 | 1.1% | 1.0% | ||
| Q1 25 | 3.7% | 1.6% | ||
| Q4 24 | 5.6% | 3.5% | ||
| Q3 24 | 1.9% | 1.9% | ||
| Q2 24 | 4.7% | 2.4% | ||
| Q1 24 | 3.9% | 2.2% |
现金转化率ASLEVCYT
| Q4 25 | 2.11× | 1.28× | ||
| Q3 25 | — | 2.34× | ||
| Q2 25 | 2.31× | — | ||
| Q1 25 | — | 0.76× | ||
| Q4 24 | 13.89× | 4.80× | ||
| Q3 24 | 20.52× | 1.98× | ||
| Q2 24 | — | 5.16× | ||
| Q1 24 | -3.42× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
ASLE
| Products | $57.8M | 64% |
| Maintenance | $23.2M | 26% |
| Leasing Arrangements | $9.9M | 11% |
VCYT
| Testing | $135.8M | 97% |
| Products | $3.8M | 3% |
| Biopharmaceutical And Other | $686.0K | 0% |
